본문 바로가기

Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
NEURO-ONCOLOGY26(12) · pp.2352 · 2024
피인용
Web of Science 32Scopus 36
FWCI (Scopus)
3.91
JCR IF
JCR 2023 16.4
ISSN
1522-8517

저자

  1. Kim, Hyery제1저자Univ Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea
  2. Yoon, Hee MangUniv Ulsan, Childrens Hosp, Asan Med Ctr, Dept Radiol,Coll Med, Seoul, South Korea
  3. Kim, Eun KeyUniv Ulsan, Childrens Hosp, Asan Med Ctr, Dept Plast Surg,Coll Med, Seoul, South Korea
  4. Ra, Young ShinUniv Ulsan, Coll Med, Asan Med Ctr, Dept Neurosurg,Childrens Hosp, Seoul, South Korea
  5. Kim, Hyo-WonUniv Ulsan, Asan Med Ctr, Coll Med, Dept Psychiat,Childrens Hosp, Seoul, South Korea
  6. Yum, Mi-SunUniv Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea
  7. Kim, Min-JeeUniv Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea
  8. Baek, Jae SukUniv Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea
  9. Sung, Yu SubUniv Ulsan, Coll Med, Dept Convergence Med, Seoul, South Korea
  10. Lee, Sang MinUniv Ulsan, Coll Med, Asan Med Ctr, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
  11. Lim, Hyeong-SeokUniv Ulsan, Coll Med, Asan Med Ctr, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
  12. Lee, Byung JooUniv Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea
  13. Lim, Hyun TaekUniv Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea
  14. Kim, DohyungUniv Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea
  15. Yoon, JiheeUniv Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea
  16. Bae, HyunwooUniv Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea
  17. Hwang, SoojinUniv Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea
  18. Choi, Yun-HaUniv Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea
  19. Kim, Kyung AhUniv Ulsan, Coll Med, Med Genet Ctr, Asan Med Ctr, Seoul, South Korea
  20. Choi, In HeeUniv Ulsan, Dept Genet Counseling, Coll Med, Seoul, South Korea
  21. Lee, Seung WonUniv Ulsan, Radiat Oncol Lab, Coll Med, Seoul, South Korea
  22. 박수정Pusan Natl Univ, Sch Korean Med, Pusan, South Korea
  23. Lee, Beom Hee교신저자Univ Ulsan, Dept Pediat, Coll Med, Asan Med Ctr,Childrens Hosp, Seoul, South Korea

초록

Background The MEK inhibitor, selumetinib, reduces plexiform neurofibroma (PN) in pediatric patients with neurofibromatosis type 1 (NF1). Its safety and efficacy in adults with PN and effectiveness in other NF1 manifestations (eg, neurocognitive function, growth reduction, and caf & eacute;-au-lait spots) are unknown. Methods This open-label, phase II trial enrolled 90 pediatric or adult NF1 patients with inoperable, symptomatic, or potentially morbid, measurable PN (>= 3 cm). Selumetinib was administered at doses of 20 or 25 mg/m2 or 50 mg q 12 hours for 2 years. Pharmacokinetics, PN volume, growth parameters, neurocognitive function, caf & eacute;-au-lait spots, and quality of life (QoL) were evaluated. Results Fifty-nine children and 30 adults (median age, 16 years; range, 3-47) received an average of 22 +/- 5 (4-26) cycles of selumetinib. Eighty-eight (98.9%) out of 89 per-protocol patients showed volume reduction in the target PN (median, 40.8%; 4.2%-92.2%), and 81 (91%) patients showed partial response (>= 20% volume reduction). The response lasted until cycle 26. Scores of neurocognitive functions (verbal comprehension, perceptual reasoning, processing speed, and full-scale IQ) significantly improved in both pediatric and adult patients (P < .05). Prepubertal patients showed increases in height score and growth velocity (P < .05). Caf & eacute;-au-lait spot intensity decreased significantly (P < .05). Improvements in QoL and pain scores were observed in both children and adults. All adverse events were CTCAE grade 1 or 2 and were successfully managed without drug discontinuation. Conclusions Selumetinib decreases PN volume in the majority of pediatric and adult NF1 patients while also showing efficacy in nonmalignant diverse NF1 manifestations. Trial Registration Cris.nih.go.kr Identifier (KCT0003700).

키워드

Caf & eacute-au-Lait spotsmitogen-activated protein kinase kinasesneurofibromatosis 1neurofibromaplexiformINHIBITORHEALTHYMRI

식별자

Scopus EID
2-s2.0-85212456976
WoS UID
001280404500001